Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
Structure Therapeutics (NASDAQ: GPCR) has announced multiple poster presentations at ObesityWeek® 2024, scheduled for November 3-6, 2024 in San Antonio, TX. The company will present three posters focusing on obesity treatment innovations:
1. A presentation on novel oral small molecule dual amylin and calcitonin receptor agonists for obesity treatment
2. Research on drug design principles and PK/PD of GSBR-1290, a small molecule GLP-1RA
3. Clinical results showing significant weight changes at 12 weeks with GSBR-1290
All presentations will take place in Exhibit Hall 4, with specific sessions scheduled for November 3-4.
Structure Therapeutics (NASDAQ: GPCR) ha annunciato numerosi poster che saranno presentati a ObesityWeek® 2024, in programma dal 3 al 6 novembre 2024 a San Antonio, TX. L'azienda presenterà tre poster incentrati sulle innovazioni nel trattamento dell'obesità:
1. Una presentazione su nuovi agonisti orali a piccole molecole che sono duali per i recettori dell'amilyn e della calcitonina nel trattamento dell'obesità
2. Ricerca sui principi di progettazione dei farmaci e PK/PD di GSBR-1290, un agonista del recettore GLP-1 a piccole molecole
3. Risultati clinici che mostrano cambiamenti significativi nel peso dopo 12 settimane con GSBR-1290
Tutte le presentazioni si svolgeranno nella Exhibit Hall 4, con sessioni specifiche programmate per il 3 e 4 novembre.
Structure Therapeutics (NASDAQ: GPCR) ha anunciado múltiples presentaciones de pósters en ObesityWeek® 2024, programado para el 3-6 de noviembre de 2024 en San Antonio, TX. La empresa presentará tres pósters centrados en innovaciones para el tratamiento de la obesidad:
1. Una presentación sobre nuevos agonistas orales de pequeñas moléculas duales para los receptores de amiloide y calcitonina en el tratamiento de la obesidad
2. Investigación sobre principios de diseño de fármacos y PK/PD de GSBR-1290, un GLP-1RA de pequeñas moléculas
3. Resultados clínicos que muestran cambios significativos en el peso a las 12 semanas con GSBR-1290
Todas las presentaciones tendrán lugar en el Exhibit Hall 4, con sesiones específicas programadas para el 3 y 4 de noviembre.
Structure Therapeutics (NASDAQ: GPCR)는 ObesityWeek® 2024에서 여러 포스터 발표를 발표한다고 밝혔습니다. 이 행사는 2024년 11월 3일부터 6일까지 텍사스주 샌안토니오에서 열립니다. 회사는 비만 치료 혁신에 초점을 맞춘 세 개의 포스터를 발표할 예정입니다:
1. 비만 치료를 위한 새로운 경구용 소분자 이중 아밀린 및 칼시토닌 수용체 작용제에 대한 발표
2. GSBR-1290의 약물 설계 원칙 및 PK/PD에 대한 연구, 소분자 GLP-1RA
3. GSBR-1290으로 12주 동안의 체중 변화에 대한 임상 결과
모든 발표는 전시 홀 4에서 진행되며, 11월 3일과 4일에 특정 세션이 예정되어 있습니다.
Structure Therapeutics (NASDAQ: GPCR) a annoncé plusieurs présentations de posters lors de la ObesityWeek® 2024, prévue du 3 au 6 novembre 2024 à San Antonio, TX. L'entreprise présentera trois posters axés sur les innovations en matière de traitement de l'obésité :
1. Une présentation sur de nouveaux agonistes oraux à petite molécule, duals pour les récepteurs d'amylin et de calcitonine, pour le traitement de l'obésité
2. Recherche sur les principes de conception des médicaments et la PK/PD de GSBR-1290, un GLP-1RA à petite molécule
3. Résultats cliniques montrant des changements significatifs de poids après 12 semaines avec GSBR-1290
Toutes les présentations auront lieu dans le Hall d'Exposition 4, avec des sessions spécifiques prévues pour les 3 et 4 novembre.
Structure Therapeutics (NASDAQ: GPCR) hat mehrere Posterpräsentationen auf der ObesityWeek® 2024 angekündigt, die vom 3. bis 6. November 2024 in San Antonio, TX, stattfinden wird. Das Unternehmen wird drei Poster vorstellen, die sich auf Innovationen zur Behandlung von Fettleibigkeit konzentrieren:
1. Eine Präsentation über neuartige orale kleine Molekül-Dual-Amylin- und Calcitonin-Rezeptor-Agonisten zur Behandlung von Fettleibigkeit
2. Forschung zu den Prinzipien des Wirkstoffdesigns und PK/PD von GSBR-1290, einem kleinen Molekül GLP-1RA
3. Klinische Ergebnisse, die signifikante Gewichtsveränderungen nach 12 Wochen mit GSBR-1290 zeigen
Alle Präsentationen finden in der Exhibit Hall 4 statt, mit speziellen Sitzungen, die für den 3. und 4. November geplant sind.
- None.
- None.
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX.
Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity Treatment
Poster Number: Poster 128
Date/Time: Sunday, November 3, 7:30 p.m. – 8:30 p.m. CT
Location: Exhibit Hall 4
Title: Drug Design Principles and Pharmacokinetics/Pharmacodynamics of GSBR-1290, a Small Molecule GLP-1RA
Poster Number: Poster 337
Date/Time: Monday, November 4, 2:30 p.m. – 3:30 p.m. CT
Location: Exhibit Hall 4
Title: Significant and Clinically Relevant Weight Changes at 12 Weeks with Small Molecule GLP-1RA, GSBR-1290
Poster Number: Poster 342
Date/Time: Monday, November 4, 2:30 p.m. – 3:30 p.m. CT
Location: Exhibit Hall 4
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
What presentations will Structure Therapeutics (GPCR) give at ObesityWeek 2024?
When and where will Structure Therapeutics (GPCR) present at ObesityWeek 2024?
What are the key findings of GSBR-1290 that Structure Therapeutics (GPCR) will present?
